Abstract is: Romiplostim, sold under the brand name Nplate among others, is a fusion protein analog of thrombopoietin, a hormone that regulates platelet production.
| P267 | ATC code | B02BX04 |
| P231 | CAS Registry Number | 267639-76-9 |
| P592 | ChEMBL ID | CHEMBL1201832 |
| P715 | DrugBank ID | DB05332 |
| P646 | Freebase ID | /m/04gpf4k |
| P595 | Guide to Pharmacology Ligand ID | 6974 |
| P665 | KEGG ID | D08990 |
| P10245 | MedlinePlus drug identifier | a609008 |
| P6366 | Microsoft Academic ID | 2776915898 |
| P1748 | NCI Thesaurus ID | C52183 |
| P2115 | NDF-RT ID | N0000177934 |
| P10283 | OpenAlex ID | C2776915898 |
| P4235 | PatientsLikeMe treatment ID | romiplostim |
| P3345 | RxNorm ID | 805452 |
| P652 | UNII | GN5XU2DXKV |
| P11143 | WikiProjectMed ID | Romiplostim |
| P3780 | active ingredient in | Nplate | Q29006237 |
| P4250 | defined daily dose | 30 | |
| P1552 | has characteristic | biopharmaceutical | Q679692 |
| P366 | has use | medication | Q12140 |
| P2175 | medical condition treated | thrombocytopenia | Q585285 |
| myelodysplastic syndrome | Q954625 | ||
| P129 | physically interacts with | MPL proto-oncogene, thrombopoietin receptor | Q7798344 |
| P3489 | pregnancy category | US pregnancy category C | Q28123617 |
| P9989 | stylized name | romiPLOStim | |
| P2275 | World Health Organisation international non-proprietary name | romiplostim |
FileName: Nplate (Romiplostim) 250mkg.jpg
Description: Nplate packing with russian label
Artist: Fnaq
Work is copyrighted.
License: CC BY-SA 4.0
Attribution is required.
| Q66034402 | Chemotherapy, SU5416, Radiation Therapy, and Surgery in Treating Patients With Soft Tissue Sarcoma |
| Q66033915 | Combination Chemotherapy With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer |
| Q66033853 | Leucovorin and Fluorouracil With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer |
| Q62110926 | Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial Therapy |
| Q62110315 | SU5416 Combined With Gemcitabine and Cisplatin in Treating Patients With Advanced Solid Tumors |
| Q66035010 | SU5416 Compared to Dexamethasone in Treating Patients With Progressive Prostate Cancer That Has Not Responded to Hormone Therapy |
| Q66035359 | SU5416 Plus Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer |
| Q66038876 | SU5416 and Carboplatin to Treat Ovarian Cancer |
| Q66037636 | SU5416 and Doxorubicin in Treating Patients With Stage IIIB or Stage IV Inflammatory Breast Cancer |
| Q66035774 | SU5416 and Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer |
| Q66036557 | SU5416 and Irinotecan in Treating Patients With Advanced Colorectal Cancer |
| Q66034555 | SU5416 and Paclitaxel in Treating Patients With Advanced Cancer |
| Q66037665 | SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and Neck |
| Q66039983 | SU5416 in Patients With AIDS-Related Kaposi's Sarcoma Who Have Not Responded to Treatment |
| Q66035778 | SU5416 in Treating Children With Recurrent or Progressive Brain Tumors |
| Q62110320 | SU5416 in Treating Patients With AIDS-Related Kaposi's Sarcoma |
| Q86250487 | SU5416 in Treating Patients With AIDS-Related Kaposi's Sarcoma (1998-07-31) |
| Q66035847 | SU5416 in Treating Patients With Advanced Solid Tumors |
| Q66036175 | SU5416 in Treating Patients With Advanced or Recurrent Cancer of the Head and Neck |
| Q66035248 | SU5416 in Treating Patients With Advanced, Metastatic, or Recurrent Soft Tissue Sarcomas |
| Q66034933 | SU5416 in Treating Patients With Malignant Mesothelioma |
| Q66035734 | SU5416 in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Previous Treatment |
| Q66037544 | SU5416 in Treating Patients With Metastatic Melanoma That Has Been Previously Treated |
| Q62110925 | SU5416 in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer |
| Q66034396 | SU5416 in Treating Patients With Persistent or Recurrent Cervical Cancer |
| Q66036248 | SU5416 in Treating Patients With Recurrent Astrocytoma or Mixed Glioma That Has Not Responded to Radiation Therapy |
| Q66035859 | SU5416 in Treating Patients With Refractory or Relapsed Multiple Myeloma |
| Q66034771 | SU5416, Irinotecan, and Cisplatin in Treating Patients With Advanced Solid Tumors |
| Q66040338 | Safety and Effectiveness of Giving SU5416 to HIV-Infected Patients With AIDS-Related Kaposi's Sarcoma |
| Q66035990 | Thalidomide and SU5416 in Treating Patients With Metastatic Melanoma |
| Q33429811 | 'On-demand' romiplostim therapy in immune thrombocytopenia |
| Q91220290 | A New Tool to Assess the Epidemiology of Immune Thrombocytopenia: The Nordic Country Patient Registry for Romiplostim |
| Q100409234 | A Novel Use of Romiplostim for SARS-CoV-2-induced Thrombocytopenia |
| Q33431165 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Effect of Romiplostim on Health-Related Quality of Life in Children with Primary Immune Thrombocytopenia and Associated Burden in Their Parents |
| Q28294793 | A Phase I study of escalating doses of the tyrosine kinase inhibitor semaxanib (SU5416) in combination with irinotecan in patients with advanced colorectal carcinoma |
| Q24651047 | A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points |
| Q105789113 | A Study of Romiplostim to Prevent Low Platelet Counts in Children and Young Adults Receiving Chemotherapy for Solid Tumors |
| Q33434822 | A large observational study of patients with primary immune thrombocytopenia receiving romiplostim in European clinical practice |
| Q96133857 | A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies |
| Q47382489 | A novel MYH9 mutation in a patient with MYH9 disorders and platelet size-specific effect of romiplostim on macrothrombocytopenia |
| Q33411308 | A phase I dose escalation and pharmacodynamic study of SU5416 (semaxanib) combined with weekly cisplatin and irinotecan in patients with advanced solid tumors |
| Q33385082 | A phase II, open-label, sequential-cohort, dose-escalation study of romiplostim in Japanese patients with chronic immune thrombocytopenic purpura |
| Q83878941 | A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma |
| Q33402882 | A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine |
| Q33394959 | A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia |
| Q33404600 | A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide |
| Q48352351 | A single center experience with romiplostim for the management of chemotherapy-induced thrombocytopenia |
| Q33400911 | An open-label extension study evaluating the safety and efficacy of romiplostim for up to 3.5 years in thrombocytopenic Japanese patients with immune thrombocytopenic purpura (ITP). |
| Q33393541 | Analysis of EQ-5D scores from two phase 3 clinical trials of romiplostim in the treatment of immune thrombocytopenia (ITP). |
| Q38572743 | Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib |
| Q46438625 | Are adverse drug reaction patterns different between romiplostim and eltrombopag? 2009-2013 French PharmacoVigilance assessment |
| Q91558409 | Assessment of Self-Administration of Romiplostim in Patients with Immune Thrombocytopenic Purpura after Receipt of Home Administration Training Materials: a Cross-Sectional Study |
| Q33388267 | Assessment of immunogenicity of romiplostim in clinical studies with ITP subjects |
| Q92079174 | Assessment of romiplostim immunogenicity in adult patients in clinical trials and in a global postmarketing registry |
| Q33439931 | Bleeding tendency and platelet function during treatment with romiplostim in children with severe immune thrombocytopenic purpura |
| Q33431850 | Changes in bone marrow morphology in adults receiving romiplostim for the treatment of thrombocytopenia associated with primary immune thrombocytopenia |
| Q91220331 | Chronic immune thrombocytopenia in Denmark, Sweden and Norway: The Nordic Country Patient Registry for Romiplostim |
| Q82404896 | Combination of romiplostim and rituximab: effective therapy of severe immune thrombocytopenia |
| Q84513734 | Combined romiplostim and intravenous immunoglobulin therapy increased platelet count, facilitating splenectomy in a patient with refractory immune thrombocytopenic purpura unresponsive to monotherapy |
| Q92260333 | Comment on: Use of thrombopoietin receptor agonist (romiplostim) in neonatal autoimmune thrombocytopenia due to maternal immune thrombocytopenia |
| Q104100061 | Commentary on Khoreva et al: Romiplostim for Wiskott-Aldrich syndrome: ever-expanding horizons for the thrombopoietin receptor agonists |
| Q33404701 | Comparative net cost impact of the utilization of romiplostim and intravenous immunoglobulin for the treatment of patients with immune thrombocytopenia in Québec, Canada |
| Q44991118 | Complete radiological and metabolic response of metastatic renal cell carcinoma to SU5416 (semaxanib) in a patient with probable von Hippel-Lindau syndrome |
| Q33413675 | Concomitant use of romiplostim and chemotherapy for advanced rectal cancer associated with idiopathic thrombocytopenic purpura |
| Q33432379 | Cost Effectiveness of Romiplostim for the Treatment of Immune Thrombocytopenia (Itp) Patients In the Czech Republic |
| Q33409109 | Cost effectiveness of romiplostim for the treatment of chronic immune thrombocytopenia in Ireland |
| Q33415065 | Cost per responder associated with romiplostim and rituximab treatment for adult primary immune thrombocytopenia in France |
| Q33434852 | Cost-Effectiveness of Eltrombopag versus Romiplostim for the Treatment of Chronic Immune Thrombocytopenia in England and Wales |
| Q33427306 | Cost-Effectiveness of Romiplostim As First-Line Primary Immune Thrombocytopenia (Itp) Treatment in Adult Splenectomised Patients Who are Refractory to Other Treatments and As Second-Line Itp Treatment in Adult Non-Splenectomised Patients Where Surge |
| Q33432375 | Cost-Effectiveness of Romiplostim for the Treatment of Chronic Immune Thrombocytopenia In Portugal |
| Q59125749 | Cost-consequence model comparing eltrombopag and romiplostim in pediatric patients with chronic immune thrombocytopenia |
| Q59135184 | Cost-consequence model comparing eltrombopag versus romiplostim for adult patients with chronic immune thrombocytopenia |
| Q33419913 | Cost-effectiveness of adding rituximab to splenectomy and romiplostim for treating steroid-resistant idiopathic thrombocytopenic purpura in adults |
| Q33413487 | Cost-per-responder analysis comparing romiplostim to rituximab in the treatment of adult primary immune thrombocytopenia in Spain |
| Q33399027 | Deep vein thrombosis associated with a single dose of romiplostim in a high-risk patient |
| Q99201139 | Delayed treatment-free response after romiplostim discontinuation in pediatric chronic immune thrombocytopenia |
| Q33416541 | Development and validation of a model to predict platelet response to romiplostim in patients with lower-risk myelodysplastic syndromes |
| Q33431320 | Development of Romiplostim for Treatment of Primary Immune Thrombocytopenia From a Pharmacokinetic and Pharmacodynamic Perspective |
| Q33388773 | Development of romiplostim for the treatment of patients with chronic immune thrombocytopenia: from bench to bedside |
| Q38314244 | Development of romiplostim: a novel engineered peptibody |
| Q92706781 | Diverse functions of the thrombopoietin receptor agonist romiplostim rescue individuals exposed to lethal radiation |
| Q89937360 | Dynamic dosing of romiplostim in patients with immune thrombocytopenia purpura: Two case reports |
| Q48114122 | Effect of VEGF and its receptor antagonist SU-5416, an inhibitor of angiogenesis, on processing of the β-amyloid precursor protein in primary neuronal cells derived from brain tissue of Tg2576 mice |
| Q93214708 | Efficacy and Safety of Romiplostim Versus Eltrombopag in the Treatment of Thrombocytopenia in Patients With Wiskott-Aldrich Syndrome |
| Q101351094 | Efficacy and safety of romiplostim in refractory aplastic anaemia: a Phase II/III, multicentre, open-label study |
| Q33425644 | Efficacy and safety of the thrombopoietin receptor agonist romiplostim in patients aged ≥ 65 years with immune thrombocytopenia |
| Q33378523 | Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial |
| Q57121883 | Efficacy of romiplostim in the treatment of ITP in children: a meta-analysis |
| Q33390755 | Efficacy of romiplostim in the treatment of chemotherapy induced thrombocytopenia (CIT) in a patient with mantle cell lymphoma |
| Q101141137 | Efficacy of romiplostim in treatment of thrombocytopenia in children with Wiskott-Aldrich syndrome |
| Q33398544 | Elicitation of utility scores in Canada for immune thrombocytopenia treated with romiplostim or watch and rescue |
| Q55424728 | Eltrombopag versus romiplostim in treatment of adult patients with immune thrombocytopenia: A systematic review incorporating an indirect-comparison meta-analysis. |
| Q49534414 | Eltrombopag versus romiplostim in treatment of children with persistent or chronic immune thrombocytopenia: a systematic review incorporating an indirect-comparison meta-analysis |
| Q84193618 | Eltrombopag. Idiopathic thrombocytopenic purpura after treatment failure: romiplostim is a better option |
| Q103811218 | Equivalence Study of Semaxanib from Different Suppliers |
| Q93607791 | Erratum to: Cost Effectiveness of Romiplostim for the Treatment of Chronic Immune Thrombocytopenia in Ireland |
| Q33405179 | Erythematous rash following romiplostim administration in a patient with autoimmune lymphoproliferative syndrome |
| Q33388618 | Evaluation of bleeding and thrombotic events during long-term use of romiplostim in patients with chronic immune thrombocytopenia (ITP). |
| Q33401083 | Evaluation of bleeding-related episodes in patients with immune thrombocytopenia (ITP) receiving romiplostim or medical standard of care |
| Q33426772 | Evaluation of romiplostim for the treatment of secondary failure of platelet recovery among allogeneic hematopoietic stem cell transplant patients |
| Q92679939 | Evolution of platelet function in adult patients with chronic immune thrombocytopenia on romiplostim treatment |
| Q37084683 | Expression, purification and biological activity assessment of romiplostim biosimilar peptibody |
| Q85344602 | Extensive cerebral venous sinus thrombosis after romiplostim treatment for immune thrombocytopenia (ITP) despite severe thrombocytopenia |
| Q33421783 | Feasibility of romiplostim discontinuation in adult thrombopoietin-receptor agonist responsive patients with primary immune thrombocytopenia: an observational retrospective report in real life clinical practice |
| Q33400461 | Health-related quality of life in nonsplenectomized immune thrombocytopenia patients receiving romiplostim or medical standard of care |
| Q101127293 | High dose Romiplostim as a rescue therapy for adults with severe bleeding and refractory immune thrombocytopenia |
| Q33405562 | High doses of romiplostim induce proliferation and reduce proplatelet formation by human megakaryocytes |
| Q87209174 | High response rate but short-term effect of romiplostim in paediatric refractory chronic immune thrombocytopenia |
| Q96950982 | High-dose romiplostim accelerates hematologic recovery in patients with aplastic anemia refractory to eltrombopag |
| Q83432794 | Immune thrombocytopenia and anticoagulation: the role of romiplostim in the early treatment |
| Q33416547 | Impact of self-administration of romiplostim by patients with chronic immune thrombocytopenia compared with administration by a healthcare provider |
| Q83425288 | Increased requirement for platelet transfusions concurrent with enhanced bleeding during romiplostim treatment in a patient with thrombocytopenia due to bone marrow failure |
| Q47213468 | Initial romiplostim dosing and time to platelet response in patients with treatment refractory immune thrombocytopenia |
| Q33394842 | Investigation of the pharmacokinetics of romiplostim in rodents with a focus on the clearance mechanism |
| Q64990809 | Is There a Role for Biweekly Romiplostim in the Management of Chronic Immune Thrombocytopenia (ITP)? A Report of Three Cases. |
| Q55007521 | Leukemic mature B-cell neoplasm observed during the treatment with romiplostim in patient with thrombocytopenia and liver cirrhosis. |
| Q48507523 | Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial |
| Q84246853 | Long-term follow-up of concomitant treatment with romiplostim and warfarin in a patient with immune thrombocytopenia and severe cardiac comorbidities |
| Q26745753 | Long-term safety and efficacy of romiplostim for treatment of immune thrombocytopenia |
| Q33409611 | Long-term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials |
| Q92205699 | Long-term treatment with romiplostim and treatment-free platelet responses in children with chronic immune thrombocytopenia |
| Q33406032 | Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy |
| Q33418391 | Long-term use of the thrombopoietin-mimetic romiplostim in children with severe chronic immune thrombocytopenia (ITP). |
| Q98195631 | Mitigative efficacy of the clinical dosage administration of granulocyte colony-stimulating factor and romiplostim in mice with severe acute radiation syndrome |
| Q33427147 | Multicenter, prospective study to evaluate the efficacy of biweekly romiplostim administration in patients with immune thrombocytopenia |
| Q33403065 | Myelofibrosis associated with romiplostim treatment in a patient with immune thrombocytopenia |
| Q91168764 | Nationwide survey in France on the use of romiplostim in patients with refractory severe aplastic anemia |
| Q33430522 | New synergistic efficacy of combination of romiplostim and steroid in refractory immune thrombocytopenia patients |
| Q86122311 | No cross-resistance after sequential use of romiplostim and eltrombopag in chronic immune thrombocytopenic purpura |
| Q64057585 | Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia |
| Q94088008 | P01.041 Secondary prophylaxis with romiplostim for temozolomide-induced thrombocytopenia in newly diagnosed glioblastoma |
| Q33402430 | Patients with ≥ 20 × 10(9)/l platelets at baseline may have a prompt response to romiplostim during the early phase of treatment: an italian single-institution experience |
| Q82852496 | Persistent thrombocytopenia post auto-SCT for AML treated with romiplostim in a patient with HIV |
| Q92876264 | Pharmacodynamics of romiplostim alone and in combination with pegfilgrastim on acute radiation-induced thrombocytopenia and neutropenia in non-human primates |
| Q34293586 | Pharmacodynamics-Mediated Drug Disposition (PDMDD) and Precursor Pool Lifespan Model for Single Dose of Romiplostim in Healthy Subjects |
| Q46358056 | Pharmacokinetic and pharmacodynamic modeling of romiplostim in animals |
| Q33396191 | Pharmacological and clinical profile of romiplostim (Romiplate(®) 250 µg for s.c. injection) |
| Q33390778 | Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy |
| Q28306292 | Phase I/pilot study of SU5416 (semaxinib) in combination with irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer |
| Q107973420 | Phase II Trial of Romiplostim for Thrombocytopenia Induced by Lomustine at First Progression of MGMT Promoter-meth Glioblastoma |
| Q38817731 | Photoinduced Isomerization and Hepatoxicities of Semaxanib, Sunitinib and Related 3-Substituted Indolin-2-ones |
| Q33397133 | Pilot study of the effect of romiplostim on child health-related quality of life (HRQoL) and parental burden in immune thrombocytopenia (ITP). |
| Q93184879 | Platelet aggregation response in immune thrombocytopenia patients treated with romiplostim |
| Q59767076 | Platelet count control in immune thrombocytopenic purpura patient: Optimum romiplostim dose profile |
| Q33381948 | Platelet production bolstered with romiplostim approval. |
| Q33394075 | Portal vein thrombosis as complication of romiplostim treatment in a cirrhotic patient with hepatitis C-associated immune thrombocytopenic purpura |
| Q33402611 | Preoperative use of romiplostim in thrombocytopenic patients with chronic hepatitis C and liver cirrhosis |
| Q91544033 | Primary immune thrombocytopenia (ITP) treated with romiplostim in routine clinical practice: retrospective study from the United Kingdom ITP Registry |
| Q85913374 | Profound thrombocytopenia in patient with ITP treated with chemotherapy for breast cancer and subsequent remission after romiplostim |
| Q33407764 | Progression of bone marrow fibrosis with reticulin and collagen hyperplasia during treatment with the thrombopoietin receptor agonist romiplostim in a patient with immune thrombocytopenia |
| Q33415097 | Progression of romiplostim myelofibrosis to myeloproliferative neoplasm |
| Q59349132 | Protective Effect of the c-mpl Agonist Romiplostim on Megakaryocytopoiesis of Human CD34 Hematopoietic Progenitor Cells Exposed to Ionizing Radiation |
| Q96822489 | Proteomic changes by radio-mitigative thrombopoietin receptor agonist Romiplostim in the blood of mice exposed to lethal total-body irradiation |
| Q33410641 | Pseudothrombocytopenia in a patient receiving romiplostim for immune thrombocytopenic purpura |
| Q84151039 | Quantifying the reduction in immunoglobulin use over time in patients with chronic immune thrombocytopenic purpura receiving romiplostim (AMG 531) |
| Q50059497 | Rational modification of semaxanib and sunitinib for developing a tumor growth inhibitor targeting ATP binding site of tyrosine kinase. |
| Q33418438 | Reciprocal absence of cross-resistance between eltrombopag and romiplostim in two patients with refractory immune thrombocytopenic purpura |
| Q88003843 | Reciprocal absence of cross-resistance between eltrombopag and romiplostim in two patients with refractory immune thrombocytopenic purpura |
| Q103836512 | Regulation of Antioxidant Stress-Responsive Transcription Factor Nrf2 Target Gene in the Reduction of Radiation Damage by the Thrombocytopenia Drug Romiplostim |
| Q43077299 | Relationship of different platelet response criteria and patient outcomes in a romiplostim myelodysplastic syndromes trial |
| Q89441761 | Relative potency of the thrombopoietin receptor agonists eltrombopag, avatrombopag and romiplostim in a patient with chronic immune thrombocytopenia |
| Q33427336 | Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study |
| Q42335823 | Remissions after long-term use of romiplostim for immune thrombocytopenia |
| Q33416344 | Rescue therapy with romiplostim for refractory primary immune thrombocytopenia during pregnancy |
| Q33428815 | Response loss and development of neutralizing antibodies during long-term treatment with romiplostim in patients with immune thrombocytopenia: a case series |
| Q84548340 | Response of complex immune-mediated thrombocytopenia to romiplostim in the setting of allogeneic stem cell transplantation for chronic myelogenous leukemia |
| Q84890105 | Response of refractory immune thrombocytopenia after bone marrow transplantation to romiplostim |
| Q59281467 | Restored platelet function after romiplostim treatment in a patient with immune thrombocytopenic purpura |
| Q33414453 | Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia |
| Q84554305 | Reversible bone marrow reticulin fibrosis as a side effect of romiplostim therapy for the treatment of chronic refractory immune thrombocytopenia |
| Q26741269 | Role of romiplostim in splenectomized and nonsplenectomized patients with immune thrombocytopenia |
| Q84958692 | Romiplostim (AMG531, Nplate) for secondary failure of platelet recovery after allo-SCT |
| Q93487523 | Romiplostim (Nplate), a Treatment Option for Immune (Idiopathic) Thrombocytopenic Purpura |
| Q91506305 | Romiplostim (Nplate®) as an effective radiation countermeasure to improve survival and platelet recovery in mice |
| Q89241665 | Romiplostim Cost Per Response In Itp Treatment In the Brazilian Health Care System |
| Q33423583 | Romiplostim Treatment in Adults with Immune Thrombocytopenia of Varying Duration and Severity |
| Q90217905 | Romiplostim Treatment of Chemotherapy-Induced Thrombocytopenia |
| Q33399123 | Romiplostim administration shows reduced megakaryocyte response-capacity and increased myelofibrosis in a mouse model of MYH9-RD. |
| Q99617433 | Romiplostim and Eltrombopag in Immune Thrombocytopenia as a Second-Line Treatment |
| Q33403323 | Romiplostim and eltrombopag for immune thrombocytopenia: methods for indirect comparison |
| Q102050276 | Romiplostim as a Therapeutic Intervention for Tacrolimus-induced Immune Thrombocytopenia in a Pediatric Cardiac Transplant Patient |
| Q92274439 | Romiplostim as a transfusion saving strategy in 20 patients after heart or lung transplantation: a single centre before-after pilot study |
| Q33420059 | Romiplostim as a treatment for immune thrombocytopenia: a review |
| Q101049835 | Romiplostim as adjunctive treatment of refractory amegakaryocytic immune thrombocytopenia in a dog |
| Q33410572 | Romiplostim as early treatment for refractory primary immune thrombocytopenia |
| Q33402505 | Romiplostim as early treatment of immune thrombocytopenia with severe immunodeficiency |
| Q87653606 | Romiplostim before splenectomy in a patient with aggressive non-Hodgkin lymphoma and poor response to platelet transfusions |
| Q33398730 | Romiplostim dose response in patients with immune thrombocytopenia |
| Q36948110 | Romiplostim dose-response in patients with myelodysplastic syndromes |
| Q33398217 | Romiplostim efficacy in an acute myeloid leukemia patient with transfusion refractory thrombocytopenia |
| Q88440609 | Romiplostim for Immune Thrombocytopenia in Neuroblastoma Patients Receiving Chemotherapy |
| Q82961444 | Romiplostim for chronic lymphocytic leukemia-associated immune thrombocytopenia |
| Q33410123 | Romiplostim for delayed platelet recovery and secondary thrombocytopenia following allogeneic stem cell transplantation |
| Q33412605 | Romiplostim for management of chemotherapy-induced thrombocytopenia |
| Q95264390 | Romiplostim for management of refractory immune thrombocytopenic purpura in the immediate postpartum period |
| Q33423714 | Romiplostim for secondary thrombocytopenia following allogeneic stem cell transplantation in children |
| Q33413348 | Romiplostim for severe thrombocytopenia in the treatment of chronic hepatitis C virus infection: a new option for clinicians? |
| Q90494990 | Romiplostim for temozolomide-induced thrombocytopenia in glioblastoma: The PLATUM trial |
| Q91417546 | Romiplostim for the Emergency Management of Severe Immune Thrombocytopenia with Intracerebral Hemorrhage |
| Q98500827 | Romiplostim for the Treatment of Immune Thrombocytopenia: Spotlight on Patient Acceptability and Ease of Use |
| Q95414134 | Romiplostim for the early management of severe immune thrombocytopenia unresponsive to conventional treatment |
| Q93022562 | Romiplostim for the management of pediatric immune thrombocytopenia: drug development and current practice |
| Q53819342 | Romiplostim for the management of perioperative thrombocytopenia. |
| Q33386008 | Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura. |
| Q33386504 | Romiplostim for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a single technology appraisal |
| Q33395943 | Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized Phase III clinical trial |
| Q48258854 | Romiplostim for the treatment of glioblastoma-related paraneoplastic autoimmune thrombocytopenia refractory to conventional therapy. |
| Q33400560 | Romiplostim for the treatment of primary immune thrombocytopenia |
| Q33438904 | Romiplostim for therapy-related thrombocytopenia in pediatric malignancies |
| Q90379746 | Romiplostim for thrombocytopenia following allogeneic stem cell transplantation: A case series |
| Q91821631 | Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (ITP) for up to 1 year and in those with chronic ITP for more than 1 year: a subgroup analysis of integrated data from completed romiplostim studies |
| Q103051986 | Romiplostim in adults with newly diagnosed or persistent immune thrombocytopenia |
| Q101350927 | Romiplostim in aplastic anaemia - another tool in the armamentarium |
| Q33411082 | Romiplostim in children with chronic immune thrombocytopenia (ITP): the French experience |
| Q33394122 | Romiplostim in children with chronic refractory ITP: randomized placebo controlled study |
| Q33431697 | Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study |
| Q33386719 | Romiplostim in chronic immune thrombocytopenic purpura |
| Q48553825 | Romiplostim in chronic liver disease with severe thrombocytopenia undergoing an elective invasive procedure. |
| Q91723136 | Romiplostim in patients undergoing hematopoietic stem cell transplantation: results of a phase 1/2 multicenter trial |
| Q93044844 | Romiplostim in patients with refractory aplastic anaemia previously treated with immunosuppressive therapy: a dose-finding and long-term treatment phase 2 trial |
| Q33423291 | Romiplostim in the management of the thrombocytopenic surgical patient |
| Q33402513 | Romiplostim in the management of thrombocytopenia in a patient with autoimmune hepatitis. |
| Q98900730 | Romiplostim is effective for eltrombopag-refractory aplastic anemia: results of a retrospective study |
| Q33384267 | Romiplostim management of immune thrombocytopenic purpura |
| Q87079713 | Romiplostim mitigates dose-limiting thrombocytopenia of erucic acid for adrenomyeloneuropathy |
| Q33442715 | Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy |
| Q33392763 | Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia |
| Q33421024 | Romiplostim promotes platelet recovery in a mouse model of multicycle chemotherapy-induced thrombocytopenia |
| Q33405121 | Romiplostim resistance in secondary failure of platelet recovery |
| Q83771591 | Romiplostim reverts the thrombocytopenia in dengue hemorrhagic fever |
| Q33396652 | Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program |
| Q33439098 | Romiplostim therapy as a second-line treatment before splenectomy for refractory immune thrombocytopenia in a cirrhotic patient with iatrogenic Cushing syndrome secondary to corticosteroids |
| Q33400527 | Romiplostim therapy in children with unresponsive chronic immune thrombocytopenia. |
| Q33416575 | Romiplostim treatment allows for platelet transfusion-free liver transplantation in pediatric thrombocytopenic patient with primary sclerosing cholangitis |
| Q99235817 | Romiplostim treatment for children with immune thrombocytopenia: Results of an integrated database of five clinical trials |
| Q33383188 | Romiplostim: a breakthrough treatment for the management of immune thrombocytopenic purpura |
| Q33384183 | Romiplostim: a novel thrombopoiesis-stimulating agent |
| Q33399598 | Romiplostim: a review of its use in immune thrombocytopenia |
| Q33384475 | Romiplostim: a second-generation thrombopoietin agonist |
| Q33394402 | Romiplostim: an advance in the treatment of idiopathic thrombocytopenic purpura |
| Q81157901 | Romiplostim: an alternative treatment option besides rituximab for the management of steroid refractory idiopathic thrombocytopenic purpura |
| Q83434650 | Romiplostim: chronic therapy for a chronic disease? |
| Q84663764 | Romiplostim: leukaemia after myelodysplastic syndromes |
| Q82287248 | Romiplostim: new drug. Thrombocytopenic purpura: for selected patients, with close monitoring |
| Q104481190 | Safety and Efficacy of Eltrombopag and Romiplostim in Myelodysplastic Syndromes: A Systematic Review and Meta-Analysis |
| Q33381893 | Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. |
| Q45985398 | Safety and efficacy of romiplostim in patients with eltrombopag-resistant or -intolerant immune thrombocytopenia. |
| Q33387521 | Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia |
| Q33441008 | Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia |
| Q90027052 | Safety and efficacy of self-administered romiplostim in patients with immune thrombocytopenia: Results of an integrated database of five clinical trials |
| Q85914896 | Safety and feasibility of romiplostim treatment for patients with persistent thrombocytopenia after allogeneic stem cell transplantation |
| Q57217530 | Salvage therapy of Autoimmune Thrombocytopenic Purpura revealing non-Hodgkin Lymphoma by the thrombopoietin receptor agonist romiplostim |
| Q46555814 | Semaxanib (SUGEN). |
| Q79436818 | Semaxinib (SU5416) as a therapeutic agent targeting oncogenic Kit mutants resistant to imatinib mesylate |
| Q96219600 | Severe macrothrombocytopenia with platelet CD9 deficiency responsive to romiplostim |
| Q91042854 | Short-term dose-escalated romiplostim for preparing an adult patient with persistent newly diagnosed primary immune thrombocytopenia for splenectomy |
| Q33425628 | Signal for Thrombosis with Eltrombopag and Romiplostim: A Disproportionality Analysis of Spontaneous Reports Within VigiBase®. |
| Q94953492 | Signaling properties of murine MPL and MPL mutants after stimulation with thrombopoietin and romiplostim |
| Q83530460 | Spontaneous remission after a year of romiplostim in an adult patient with refractory primary immune thrombocytopenia |
| Q33440990 | Spotlight on romiplostim in the treatment of children with chronic immune thrombocytopenia: design, development, and potential place in therapy |
| Q54551108 | Study of differences in the VEGFR2 inhibitory activities between semaxanib and SU5205 using 3D-QSAR, docking, and molecular dynamics simulations. |
| Q33392293 | Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes |
| Q33402790 | Successful antiviral therapy for hepatitis C virus-induced cirrhosis after an increase in the platelet count with romiplostim: two case reports |
| Q33435803 | Successful early romiplostim use in a case of severe immune thrombocytopenia with critical carotid arterial injury. |
| Q33423545 | Successful switching from eltrombopag to romiplostim in a pediatric patient with refractory chronic ITP. |
| Q33417024 | Successful treatment of post-transplant thrombocytopenia with romiplostim in a pediatric patient with X-linked chronic granulomatous disease |
| Q96949912 | Successful treatment of refractory secondary immune thrombocytopenia (antiphospholipid antibody syndrome-associated) with the combination of rituximab and romiplostim at the cost of severe bone pain: A case report and review of literature |
| Q33408140 | Successful treatment of severe newly diagnosed immune thrombocytopenia involving an alveolar hemorrhage with combination therapy consisting of romiplostim, rituximab and vincristine |
| Q33404430 | Successful treatment of severe thrombocytopenia with romiplostim in a pregnant patient with systemic lupus erythematosus |
| Q33422040 | Successful treatment with rituximab and romiplostim for thrombocytopenia associated with Waldenström's macroglobulinemia initially presenting as Evans syndrome |
| Q33443533 | Sustained Remission in Patients with Primary Immune Thrombocytopenia after Romiplostim Tapering and Discontinuation: A Case Series in Real Life Management in Spain. |
| Q54988723 | TAFRO syndrome with refractory thrombocytopenia responding to tocilizumab and romiplostim: a case report. |
| Q87603670 | TPO concentrations and response to romiplostim |
| Q57942075 | Tandem Horner–Wadsworth–Emmons/Heck procedures for the preparation of 3-alkenyl-oxindoles: the synthesis of Semaxanib and GW441756 |
| Q33394636 | The development of romiplostim for patients with immune thrombocytopenia |
| Q33407279 | The efficacy and safety of romiplostim in adult patients with chronic immune thrombocytopenia |
| Q33396033 | The efficacy of romiplostim in the treatment of severe thrombocytopenia associated to Evans syndrome refractory to rituximab |
| Q37098747 | The immunopharmacologic potential of Semaxanib and new generation directed therapeutic drugs: Receptor tyrosine kinase regulation with anti-tumorigenensis/angiogenesis properties |
| Q33386010 | The road to romiplostim approval and beyond |
| Q96304947 | The role of romiplostim for pediatric patients with immune thrombocytopenia |
| Q64389265 | The thrombopoietin mimetic romiplostim leads to the complete rescue of mice exposed to lethal ionizing radiation |
| Q53809669 | The thrombopoietin mimetics eltrombopag and romiplostim in the treatment of refractory aplastic anaemia. |
| Q33414420 | The treatment for primary immune thrombocytopenia with romiplostim in adult and paediatric patients: use experience at a Spanish university hospital |
| Q49837491 | The use of romiplostim in treating chemotherapy-induced thrombocytopenia in patients with solid tumors |
| Q92425160 | Thrombopoietin Receptor Agonists: Eltrombopag and Romiplostim for the Treatment of Chronic Immune Thrombocytopenia Purpura |
| Q91312830 | Thrombopoietin level predicts response to treatment with eltrombopag and romiplostim in immune thrombocytopenia |
| Q33401211 | Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations |
| Q33432920 | Treatment of 5 dogs with immune-mediated thrombocytopenia using Romiplostim |
| Q87886589 | Treatment of acquired amegakaryocytic thrombocytopenic purpura with romiplostim |
| Q33390380 | Treatment options for chronic refractory idiopathic thrombocytopenic purpura in adults: focus on romiplostim and eltrombopag |
| Q33425552 | Two cases of thrombosis in patients with antiphospholipid antibodies during treatment of immune thrombocytopenia with romiplostim, a thrombopoietin receptor agonist |
| Q93269220 | Up-front Treatment With Romiplostim in Children With Acquired Bone Marrow Failure: A Single Institutional Pediatric Case Series |
| Q87210307 | Update on romiplostim and eltrombopag indirect comparison |
| Q92211659 | Use of Romiplostim during pregnancy as a rescue therapy in primary immune thrombocytopenia: Literature review and case description |
| Q33419404 | Use of eltrombopag after romiplostim in primary immune thrombocytopenia. |
| Q33410339 | Use of peptide thrombopoietin receptor agonist romiplostim (Nplate) in a case of primary HIV-associated thrombocytopenia |
| Q46811579 | Use of romiplostim allows for hepatitis C therapy in a HIV/HCV coinfected patient |
| Q33399983 | Use of romiplostim for primary immune thrombocytopenia in children |
| Q33404153 | Use of romiplostim in a hemodialysis patient with primary immune thrombocytopenia |
| Q33422277 | Use of romiplostim in patients with chronic idiopathic thrombocytopenic purpura during perioperative period |
| Q91876162 | Use of romiplostim in pregnancy for refractory idiopathic thrombocytopenic purpura: Two case reports with maternal and fetal outcomes and literature review |
| Q33399775 | Use of the novel thrombopoietin receptor-agonist romiplostim, in combination with steroids and immunoglobulins for the increase of platelets prior to splenectomy, in refractory immune thrombocytopenia: a case report |
| Q106977409 | Using Romiplostim to Treat Low Platelet Counts Following Chemotherapy and Autologous Hematopoietic Cell Transplantation in People With Blood Cancer |
| Q91380464 | [Successful management of primary immune thrombocytopenia with romiplostim during open heart surgery in a hemodialysis patient] |
| Q7798344 | MPL proto-oncogene, thrombopoietin receptor | physically interacts with | P129 |
| Q29006237 | Nplate | has active ingredient | P3781 |
| Category:Romiplostim | wikimedia | |
| Arabic (ar / Q13955) | روميبلوستيم | wikipedia |
| Romiplostim | wikipedia | |
| Romiplostim | wikipedia | |
| Persian (fa / Q9168) | رومیپلوستیم | wikipedia |
| Romiplostim | wikipedia | |
| אנפלייט | wikipedia | |
| Romiplostim | wikipedia | |
| ロミプロスチム | wikipedia | |
| Romiplostimas | wikipedia | |
| or | ରୋମିପ୍ଲୋଷ୍ଟିମ | wikipedia |
| Romiplostim | wikipedia | |
| Ромиплостим | wikipedia | |
| Serbo-Croatian (sh / Q9301) | Romiplostim | wikipedia |
| Romiplostim | wikipedia | |
| Romiplostim | wikipedia |
Search more.